M. Gómez-Revuelta

发表

Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort

D. Tordesillas-Gutiérrez, B. Crespo-Facorro, R. Ayesa-Arriola, 2020, The international journal of neuropsychopharmacology.

Duration of active psychosis and functional outcomes in first-episode non-affective psychosis

R. Tabarés-Seisdedos, B. Crespo-Facorro, R. Ayesa-Arriola, 2018, European Psychiatry.

Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study

B. Crespo-Facorro, P. Iruzubieta, J. Vázquez-Bourgon, 2022, Schizophrenia Research.

Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients

R. Ayesa-Arriola, J. Crespo, P. Iruzubieta, 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort

B. Crespo-Facorro, R. Ayesa-Arriola, A. Rubio-Garcia, 2022, Schizophrenia Research.

P.0570 Suicide behavior and suicide mortality during the COVID-19 Pandemic in Cantabria (Spain)

M. Gómez-Revuelta, A. De Santiago-Díaz, L. Gaite-Pindado, 2021, European Neuropsychopharmacology.

Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort

B. Crespo-Facorro, R. Ayesa-Arriola, A. Rubio-Garcia, 2022, Schizophrenia Research.

Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort

D. Tordesillas-Gutiérrez, B. Crespo-Facorro, R. Ayesa-Arriola, 2022, European Psychiatry.

Reduced glomerular filter rate in antipsychotic-naïve patients with first-episode psychosis

B. Crespo-Facorro, J. Vázquez-Bourgon, C. García-Rizo, 2022, Schizophrenia Research.

Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2022, The international journal of neuropsychopharmacology.

Understanding sex differences in long-term outcomes after a first episode of psychosis

D. Tordesillas-Gutiérrez, B. Crespo-Facorro, R. Ayesa-Arriola, 2020, npj Schizophrenia.

Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis

B. Crespo-Facorro, J. Vázquez-Bourgon, V. Ortiz-Garcia de la Foz, 2022, The international journal of neuropsychopharmacology.

Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone

B. Crespo-Facorro, A. González-Pinto, J. Vázquez-Bourgon, 2018, The international journal of neuropsychopharmacology.

Stability of schizophrenia diagnosis in a 10‐year longitudinal study on first episode of non‐affective psychosis: Conclusions from the PAFIP cohort

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2021, Acta psychiatrica Scandinavica.

Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2020, Schizophrenia Research.

Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2021, Psychological Medicine.

Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2021, European Neuropsychopharmacology.

Prolactin, metabolic and immune parameters in naïve subjects with a first episode of psychosis

B. Crespo-Facorro, J. Vázquez-Bourgon, J. Labad, 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression

J. Vázquez-Bourgon, M. Gómez-Revuelta, M. Fernández-Rodríguez, 2020, Therapeutic advances in psychopharmacology.

S0033291721003536jra 1891..1905

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2023 .

Long-term mental health impact of COVID-19 on primary care health workers in northern Spain: Results from a two-phase longitudinal study

J. Vázquez-Bourgon, M. Gómez-Revuelta, J. C. López Caro, 2023, Revista de Psiquiatría y Salud Mental.

Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2020, The international journal of neuropsychopharmacology.

Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort

D. Tordesillas-Gutiérrez, B. Crespo-Facorro, R. Ayesa-Arriola, 2019, Psychological Medicine.

Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3).

D. Tordesillas-Gutiérrez, B. Crespo-Facorro, R. Ayesa-Arriola, 2021, Revista de psiquiatria y salud mental.

Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3).

D. Tordesillas-Gutiérrez, B. Crespo-Facorro, R. Ayesa-Arriola, 2021, Revista de psiquiatria y salud mental.

Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice

C. Álamo, D. Fraguas, M. Gómez-Revuelta, 2022, International journal of psychiatry in clinical practice.

Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2020, Data in brief.

Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort

D. Tordesillas-Gutiérrez, B. Crespo-Facorro, R. Ayesa-Arriola, 2021, Schizophrenia Research.

Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis

R. Ayesa-Arriola, J. Crespo, P. Iruzubieta, 2019, Data in brief.

Metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: 3 years follow-up results from the PAFIP cohort.

B. Crespo-Facorro, R. Ayesa-Arriola, J. Vázquez-Bourgon, 2022, Spanish journal of psychiatry and mental health.